title: The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
abstract: In the present study, the immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide (Tα1-TP5) was investigated in vivo. In addition, the potential receptor of Tα1-TP5 was investigated by surface plasmon resonance (SPR) binding studies. It was found that Tα1-TP5 (305 μg/kg) alleviated immunosuppression induced by hydrocortisone (HC). Tα1-TP5 (305 μg/kg) combined with cyclophosphamide (CY) had a better tumor growth inhibitory effect than CY alone. Furthermore, Tα1-TP5 had a higher affinity (KD=6.84 μmol/L) to toll-like receptor 2 (TLR2) than Tα1 (K(D)=35.4 μmol/L), but its affinity was not significantly different from that of TP5. The results of our present work indicate that Tα1-TP5 can possibly be developed as a new immunomodulatory agent.
authors.affiliation: Key Laboratory of Chemical Biology of Natural Products, Ministry of Education, Institute of Biochemical and Biotechnological Drugs, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Yanna
authors.initials: Y
authors.lastname: Cheng
authors.forename: Xinke
authors.initials: X
authors.lastname: Zhang
authors.forename: Lei
authors.initials: L
authors.lastname: Zheng
authors.forename: Zhen
authors.initials: Z
authors.lastname: Han
authors.forename: Pingli
authors.initials: P
authors.lastname: Li
authors.forename: Yuliang
authors.initials: Y
authors.lastname: Xiao
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.forename: Fengshan
authors.initials: F
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001284:Atrophy; D051940:B7-2 Antigen / Q000378:metabolism; D003520:Cyclophosphamide / Q000494:pharmacology; D004357:Drug Synergism; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006854:Hydrocortisone / Q000494:pharmacology; D007155:Immunologic Factors / Q000378:metabolism / Q000494:pharmacology*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007371:Interferon-gamma / Q000097:blood; D008297:Male; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011485:Protein Binding; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D020349:Surface Plasmon Resonance; D000077596:Thymalfasin; D060168:Thymocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D016305:Thymopentin / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D013947:Thymosin / Q000031:analogs & derivatives* / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology; D013950:Thymus Gland / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D051195:Toll-Like Receptor 2 / Q000378:metabolism*; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D051940:B7-2 Antigen; C497965:Cd86 protein, mouse; D015395:Histocompatibility Antigens Class I; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; D013947:Thymosin; D007371:Interferon-gamma; D003520:Cyclophosphamide; D016305:Thymopentin; D000077596:Thymalfasin; D006854:Hydrocortisone
keywords: Immunoregulatory activity; Surface plasmon resonance; Synergistic anti-tumor activity; Thymosin α1–thymopentin; Toll-like receptor 2